# Tango Therapeutics, Inc.: overview TNGX · Nasdaq · CIK 1819133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tngx.md) · [Financials](/companies/tngx/financials.md) · [Filings](/companies/tngx/filings.md) · [Insiders](/companies/tngx/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-343424.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-343424). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.6](/filings/0001193125-25-263680.md) | [4.1 d](/filings/0001193125-26-092518.md) | [5.4](/filings/0001193125-26-221656.md) | [3.2](/filings/0001193125-26-343424.md) | [53.8](/filings/0001193125-25-263680.md) | [0.0 d](/filings/0001193125-26-092518.md) | [0.0](/filings/0001193125-26-221656.md) | [0.0](/filings/0001193125-26-343424.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(283.3%)](/filings/0001193125-25-263680.md) | [(993.7%) d](/filings/0001193125-26-092518.md) | [(788.8%)](/filings/0001193125-26-221656.md) | [(1287.9%)](/filings/0001193125-26-343424.md) | [26.2%](/filings/0001193125-25-263680.md) | not reported | not reported | not reported | | Net margin | % | [(251.3%)](/filings/0001193125-25-263680.md) | [(915.0%) d](/filings/0001193125-26-092518.md) | [(739.5%)](/filings/0001193125-26-343424.md) | [(1221.4%)](/filings/0001193125-26-343424.md) | [29.5%](/filings/0001193125-25-263680.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001193125-25-263680.md) | not reported | [(0.36)](/filings/0001193125-26-221656.md) | [(0.35)](/filings/0001193125-26-343424.md) | [0.13](/filings/0001193125-25-263680.md) | not reported | [(0.32)](/filings/0001193125-26-221656.md) | [(0.37)](/filings/0001193125-26-343424.md) | | Free cash flow | $m | [(33.5) d](/filings/0001193125-25-263680.md) | [(36.8) d](/filings/0001193125-26-092518.md) | [(41.7)](/filings/0001193125-26-221656.md) | [(37.1) d](/filings/0001193125-26-343424.md) | [(31.1) d](/filings/0001193125-25-263680.md) | [(29.9) d](/filings/0001193125-26-092518.md) | [(44.4)](/filings/0001193125-26-221656.md) | [(38.9) d](/filings/0001193125-26-343424.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [37.0](/filings/0000950170-23-009854.md) | [24.9](/filings/0000950170-25-028353.md) | [36.5](/filings/0001193125-26-092518.md) | [42.1](/filings/0001193125-26-092518.md) | [62.4](/filings/0001193125-26-092518.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(157.1%)](/filings/0000950170-23-009854.md) | [(446.8%)](/filings/0000950170-25-028353.md) | [(312.6%)](/filings/0001193125-26-092518.md) | [(346.1%)](/filings/0001193125-26-092518.md) | [(178.4%)](/filings/0001193125-26-092518.md) | | Net margin | % | [(157.2%)](/filings/0000950170-23-009854.md) | [(435.1%)](/filings/0000950170-25-028353.md) | [(278.5%)](/filings/0001193125-26-092518.md) | [(309.7%)](/filings/0001193125-26-092518.md) | [(162.9%)](/filings/0001193125-26-092518.md) | | Diluted EPS | $ per share | [(0.94)](/filings/0000950170-23-009854.md) | [(1.23)](/filings/0000950170-25-028353.md) | [(1.08)](/filings/0001193125-26-092518.md) | [(1.19)](/filings/0001193125-26-092518.md) | [(0.87)](/filings/0001193125-26-092518.md) | | Free cash flow | $m | [(61.4)](/filings/0000950170-23-009854.md) | [(117)](/filings/0000950170-25-028353.md) | [(120)](/filings/0001193125-26-092518.md) | [(132)](/filings/0001193125-26-092518.md) | [(140)](/filings/0001193125-26-092518.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tngx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $434.5m | 13,900,620 | | Added +600,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $388.8m | 12,438,444 | | Added +3,690,399 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $385.5m | 12,333,339 | | Added +2,427,420 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $383.8m | 12,277,000 | | Added +3,179,589 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $340.0m | 10,876,219 | | Unchanged | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $312.0m | 9,980,620 | | Added +4,904,228 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $283.9m | 9,081,201 | | Reduced −1,449,870 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $198.7m | 6,357,523 | | Added +2,347,844 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $193.2m | 6,179,364 | | Added +522,259 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $186.9m | 5,979,806 | | Added +1,327,912 | ## Recent filings [All 416 filings](/companies/tngx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 06:36 ET | [8-K](/filings/0001193125-26-429423.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429423 | | 2026-08-11 | 21:13 ET | [8-K](/filings/0001193125-26-344997.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-344997 | | 2026-08-11 | 11:20 ET | [8-K](/filings/0001193125-26-343434.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343434 | | 2026-08-11 | 11:12 ET | [10-Q](/filings/0001193125-26-343424.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343424 | | 2026-08-07 | 10:41 ET | [8-K/A](/filings/0001193125-26-339070.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-339070 | | 2026-08-06 | 21:30 ET | [8-K](/filings/0001193125-26-338480.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-338480 | | 2026-06-23 | 21:19 ET | [8-K](/filings/0001193125-26-279788.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-279788 | | 2026-06-10 | 21:22 ET | [8-K](/filings/0001193125-26-266078.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-266078 | | 2026-06-08 | 11:15 ET | [8-K](/filings/0001193125-26-260679.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-260679 | | 2026-06-04 | 21:19 ET | [8-K](/filings/0001193125-26-257760.md) | 5.07 Shareholder vote results | 0001193125-26-257760 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092518.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/da684fb6-b94c-46b1-8e81-518496cc097e) ## About the filer - CIK: 1819133 - Tickers: TNGX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.